AbbVie Inc. (NYSE:ABBV) Stock Has Average Price Target of $279.86

Key Points

• Analysts remain broadly positive: AbbVie has a “Moderate Buy” consensus from 30 firms, with 23 buy ratings, one strong buy and six holds. The average 12-month price target is $279.86.
• SKYRIZI growth supports AbbVie’s post-Humira strategy: The FDA approved a more convenient subcutaneous induction regimen for Crohn’s disease, while the company’s dividend remains an important defensive attraction.
• Investors face mixed near-term signals: AbbVie shares are trading near their 52-week high at a premium valuation, and analysts are cautious ahead of earnings; lutikizumab’s trial success was tempered by concerns about its competitiveness.

AbbVie Inc. (NYSE:ABBV - Get Free Report) has been assigned an average rating of "Moderate Buy" from the thirty research firms that are presently covering the stock, MarketBeat reports. Six analysts have rated the stock with a hold rating, twenty-three have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $279.86.

Several research firms have commented on ABBV. Bank of America reiterated a "buy" rating on shares of AbbVie in a research note on Tuesday, September 8th. Scotiabank raised their target price on AbbVie from $280.00 to $320.00 and gave the company an "outperform" rating in a research report on Tuesday, October 6th. BNP Paribas Exane lifted their price target on AbbVie from $218.00 to $247.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 11th. Royal Bank Of Canada reiterated an "outperform" rating and set a $280.00 price target on shares of AbbVie in a research report on Tuesday, October 13th. Finally, Argus increased their price objective on AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

AbbVie Stock Up 0.2%

Shares of NYSE ABBV opened at $285.66 on Friday. The company's 50-day simple moving average is $266.33 and its 200-day simple moving average is $241.77. AbbVie has a 52-week low of $190.75 and a 52-week high of $291.40. The firm has a market cap of $504.70 billion, a price-to-earnings ratio of 80.69, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company's quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie will post 13.93 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. AbbVie's payout ratio is presently 195.48%.

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Lifelong Wealth Advisors Inc. grew its stake in shares of AbbVie by 2.1% in the 3rd quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company's stock valued at $459,000 after buying an additional 36 shares in the last quarter. James T. Borello RIA raised its position in AbbVie by 3.5% during the third quarter. James T. Borello RIA now owns 1,192 shares of the company's stock valued at $312,000 after acquiring an additional 40 shares in the last quarter. ACT Advisors LLC. raised its position in AbbVie by 2.5% during the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock valued at $425,000 after acquiring an additional 41 shares in the last quarter. Willner & Heller LLC raised its position in AbbVie by 0.7% during the second quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock valued at $1,472,000 after acquiring an additional 43 shares in the last quarter. Finally, B.O.S.S. Retirement Advisors LLC lifted its stake in AbbVie by 3.1% in the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock valued at $359,000 after acquiring an additional 43 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

About AbbVie

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.